The majority of patients with chronic kidney disease are currently treated with dialyzers containing synthetic membranes. Of all the dialysis membranes made from these polymers, 93% are from the parent polyarylsulfone family of which 71% are from polysulfone (PSu) and 22% from polyethersulfone. The preference of nephrologists for PSu dialyzers signifies their versatility in terms of meeting the solute and fluid removal demands for all treatment modalities (low-and high-flux dialysis, online hemodiafiltration, hemofiltration). The unprecedented success and widespread usage of PSu membranes is attributed, in addition to efficient removal of a broad spectrum of uremic toxins, to other criteria required of modern dialysis therapies. Namely, effective endotoxin retention capacity, pronounced intrinsic biocompatibility and low cytotoxicity are factors which all contribute to minimal adverse clinical sequelae. Furthermore, PSu by virtue of its high thermal stability can be sterilized with steam, the preferred mode of sterilization as it does not have the disadvantages associated with other sterilization methods. However, there are significant differences between membranes made from PSu due to differences in membrane polymer recipes and manufacturing technologies. Although PSu may be the main constituent, these membranes are blended with other polymers, e.g. hydrophilizing agents, such as polyvinylpyrrolidone to give each membrane its characteristic profile. The relative amounts of the two (or more) co-polymers as well as the spinning conditions provide a fingerprint of each membrane in terms of solute separation characteristics, biocompatibility, cytotoxicity or endotoxin retention capabilities. PSu membrane-based dialyzers thus fulfill the crucial therapy requirements of current treatment modalities to varying extents. Thereby, different effects towards patient outcomes and treatment safety are achieved.
Copyright © 2011 S. Karger AG, Basel.